Tumor Biology

, Volume 37, Issue 11, pp 14915–14921 | Cite as

Endocan reduces the malign grade of gastric cancer cells by regulating associated protein expression

  • Zhang Sumei
  • Chen Shaolong
  • Wei Xiang
  • Qi Yinliang
  • Zhou Qing
  • Wang YuanEmail author
Original Article


Endocan, which has been identified to be low expressed in gastric cancer, was found to be positively related to the differentiation level of gastric cancer in vivo and in vitro. In the present study, we aimed to investigate the role of endocan in gastric adenocarcinoma cell line SGC7901 by artificially upregualting or downregulating endocan expression using endocan recombinant vector or specific small interfering RNA (siRNA)-targeting endocan gene, respectively. The effects of endocan recombinant vector-mediated over-expressing and siRNA-mediated endocan silencing on the differentiation, migration, and apoptosis of SGC7901 cells were assessed. Furthermore, the primary molecular mechanisms of endocan were explored by testing the expression alterations of associated protein in SGC7901 along endocan over-expression or knockdown. We found that over-expression of endocan reduced the migration but promoted the differentiation and apoptosis of SGC7901 cells. While, knockdown of endocan did just the opposite. Some molecules were found to participate in endocan-mediated anti-tumor effects, such as p53, caspase 3, and MMP-9. In conclusion, our findings suggest that endocan plays an anti-carcinogenic role in gastric cancer development and progression and might serve as a prognostic biomarker as well as a potential therapeutic target for gastric cancer.


Gastric cancer Endocan Biomarker 



This study was supported by the Fund for Young Talents in the College of Anhui Province (No. 2012SQRL067), National Natural Science Foundation of China (No. 81201907), National Natural Science Foundation of China (No. 81272399), National Natural Science Foundation of China (No. 81470568), and Research Fund for Doctors in Anhui Medical University (XJ201229).

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L, et al. The incidences and mortalities of major cancers in China, 2009. Chin J Cancer. 2013;32:106–12.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zhang SM, Zuo L, Gui SY, Zhou Q, Wei W, Wang Y. Induction of cell differentiation and promotion of endocan gene expression in stomach cancer by melatonin. Mol Biol Rep. 2012;39:2843–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Lassalle P, Molet S, Janin A, Heyden JV, Tavernier J, Fiers W, et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem. 1996;271:20458–64.CrossRefPubMedGoogle Scholar
  5. 5.
    Bechard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem. 2001;276:48341.PubMedGoogle Scholar
  6. 6.
    Miao Y, Zong M, Jiang T, Yuan X, Guan S, Wang Y, et al. A comparative analysis of ESM-1 and vascular endothelial cell marker (CD34/CD105) expression on pituitary adenoma invasion. Pituitary. 2016;19:194–201.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ozaki K, Toshikuni N, George J, Minato T, Matsue Y, Arisawa T, et al. Serum endocan as a novel prognostic biomarker in patients with hepatocellular carcinoma. J Cancer. 2014;5:221–30.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Abid MR, Yi X, Yano K, Shih SC, Aird WC. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res. 2006;72:136–45.CrossRefPubMedGoogle Scholar
  9. 9.
    Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, et al. Endocan expression and relationship with survival in human nonsmall cell lung cancer. Clin cancer res off J Am Assoc. Cancer Res. 2006;12:4575–82.Google Scholar
  10. 10.
    Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, et al. Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol. 2012;22:757–64.CrossRefPubMedGoogle Scholar
  11. 11.
    Maurage CA, Adam E, Mineo JF, Sarrazin S, Debunne M, Siminski RM, et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol. 2009;68:633–41.CrossRefPubMedGoogle Scholar
  12. 12.
    Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, et al. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp Cell Res 2007; 313: 1285–1294.Google Scholar
  13. 13.
    Xu Z, Zhang SM, Zhou Q, Wang Y, Xia RX. Endocan, a potential prognostic and diagnostic biomarker of acute leukemia. Mol Cell Biochem 2014; 395: 117–123.Google Scholar
  14. 14.
    Zuo L, Lu M, Zhou Q, Wei W, Wang Y. Butyrate suppresses proliferation and migration of RKO colon cancer cells though regulating endocanexpression by MAPK signaling pathway. Food Chem Toxicol. 2013;62:892–900.CrossRefPubMedGoogle Scholar
  15. 15.
    Zuo L, Zhang SM, RL H, Zhu HQ, Zhou Q, Gui SY, et al. Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol. 2008;14(28):4562–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002;2:563–72.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhang SM, Qi YL, Zhang HT, He W, Zhou Q, Gui SY, et al. Melatonin inhibits cell growth and migration,but promotes apoptosis in gastric cancer cell line, SGC7901. Biotech Histochem. 2013;88(6):281–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Leroy X, Aubert S, Zini L, Franquet H, Kervoaze G, Villers A, et al. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology. 2010;56:180–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Hatfield KJ, Lassalle P, Leiva RA, Lindås R, Wendelboe Ø, Bruserud Ø. Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology. 2011;16:351–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Bao L, Liu F, Guo HB, Li Y, Tan BB, Zhang WX, et al. Naringenin inhibits proliferation, migration, and invasion as well as induces apoptosis of gastric cancer SGC7901 cell line by downregulation of AKT pathway. Tumour Biol. 2016; [Epub ahead of print].Google Scholar
  21. 21.
    Sampieri CL, de la Peña S, Ochoa-Lara M, Zenteno-Cuevas R, León-Córdoba K. Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis. World J Gastroenterol. 2010;16:1500–5.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Fields GB. New strategies for targeting matrix metalloproteinases. Matrix Biol 2015; 44–46:239–246.Google Scholar
  23. 23.
    Major apoptotic mechanisms and genes involved in apoptosis. Kiraz Y, Adan A, Kartal Yandim M, Baran Y. Tumour Biol. 2016 Apr 9.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Zhang Sumei
    • 1
  • Chen Shaolong
    • 1
  • Wei Xiang
    • 1
  • Qi Yinliang
    • 1
    • 2
  • Zhou Qing
    • 1
  • Wang Yuan
    • 1
    Email author
  1. 1.Laboratory of Molecular Biology and Department of BiochemistryKey Laboratory of Gene Research of Anhui ProvinceHefeiPeople’s Republic of China
  2. 2.General Department of Hyperbaric OxygenThe Second People’s Hospital of HefeiHefeiChina

Personalised recommendations